Luo Xiaojun, Wang Yang, Zhang Xi, Liu Wenbin
Hepatic Biliary and Pancreatic Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
J Oncol. 2022 Aug 29;2022:5735462. doi: 10.1155/2022/5735462. eCollection 2022.
Hepatocellular carcinoma (HCC) is a high-mortality malignant tumor with genetic and phenotypic heterogeneity, making predicting clinical outcomes challenging. The purpose of this investigation was to examine the potential usefulness of lncRNA DDX11 antisense RNA 1 (DDX11-AS1) as a biomarker for diagnosis and prognosis in hepatocellular carcinoma (HCC). The TCGA-LIHC datasets were searched for patients' clinical information and RNA-seq data, which were then collected. Relative expression levels of DDX11-AS1 in HCC tissues were determined by qRT-PCR. In order to test the sensitivity and specificity of the DDX11-AS1 receiver, receiver operating characteristic curves were utilized. The association of DDX11-AS1 expression with clinicopathological factors or prognosis was statistically analyzed. We found that the levels of DDX11-AS1 were higher in HCC specimens than in normal specimens. ROC analysis showed that DDX11-AS1 was a useful marker for discriminating HCC tissues from normal nontumor specimens. According to the results of clinical tests, a high level of DDX11-AS1 expressions was significantly related to the pathologic stage (=0.015) and the histologic grade ( < 0.001). Survival studies indicated that patients with higher DDX11-AS1 expression had a significantly poorer overall survival (=0.005) and progression-free interval (=0.003) than those with lower DDX11-AS1 expression. Multivariate survival analysis verified that DDX11-AS1 expression level was an independent predictor for HCC patients. Overall, DDX11-AS1 may serve as a tumor promotor during HCC progression, and its high level may be a potential marker for HCC patients.
肝细胞癌（HCC）是一种具有遗传和表型异质性的高死亡率恶性肿瘤，这使得预测临床结果具有挑战性。本研究的目的是探讨长链非编码RNA DDX11反义RNA 1（DDX11-AS1）作为肝细胞癌（HCC）诊断和预后生物标志物的潜在用途。在TCGA-LIHC数据集中搜索患者的临床信息和RNA测序数据，然后进行收集。通过qRT-PCR测定HCC组织中DDX11-AS1的相对表达水平。为了测试DDX11-AS1接受者的敏感性和特异性，使用了受试者工作特征曲线。对DDX11-AS1表达与临床病理因素或预后的相关性进行了统计学分析。我们发现，HCC标本中DDX11-AS1的水平高于正常标本。ROC分析表明，DDX11-AS1是区分HCC组织与正常非肿瘤标本的有用标志物。根据临床试验结果，高水平的DDX11-AS1表达与病理分期（=0.015）和组织学分级（<0.001）显著相关。生存研究表明，DDX11-AS1表达较高的患者的总生存期（=0.005）和无进展生存期（=0.003）明显低于DDX11-AS1表达较低的患者。多变量生存分析证实，DDX11-AS1表达水平是HCC患者的独立预测因子。总体而言，DDX11-AS1可能在HCC进展过程中作为肿瘤促进因子，其高水平可能是HCC患者的潜在标志物。
